It is often a long and rigorous process to assist our clients with developing measures to support labeling claims.  Last week, two measures we developed were used to document treatment benefit from the perspective of patients for two of our sponsors and are captured in the product labels for atogepant and maralixibat.  The first, was the Activity Impairment in Migraine Diary (AIM-D) in the prevention of episodic migraine and the second was the Itch Reported Outcome Measure Observer Report [ItchRO (Obs)] in Alagille syndrome.  Many thanks to the researchers at Endpoint Outcomes for their hard work in putting the patient’s voice at the center of drug development.